Antimicrobial resistance in developing countries. Part I: recent trends and current status

Lancet Infect Dis. 2005 Aug;5(8):481-93. doi: 10.1016/S1473-3099(05)70189-4.


The global problem of antimicrobial resistance is particularly pressing in developing countries, where the infectious disease burden is high and cost constraints prevent the widespread application of newer, more expensive agents. Gastrointestinal, respiratory, sexually transmitted, and nosocomial infections are leading causes of disease and death in the developing world, and management of all these conditions has been critically compromised by the appearance and rapid spread of resistance. In this first part of the review, we have summarised the present state of resistance in these infections from the available data. Even though surveillance of resistance in many developing countries is suboptimal, the general picture is one of accelerating rates of resistance spurred by antimicrobial misuse and shortfalls in infection control and public health. Reservoirs for resistance may be present in healthy human and animal populations. Considerable economic and health burdens emanate from bacterial resistance, and research is needed to accurately quantify the problem and propose and evaluate practicable solutions. In part II, to be published next month, we will review potential containment strategies that could address this burgeoning problem.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Child, Preschool
  • Communicable Diseases* / epidemiology
  • Communicable Diseases* / mortality
  • Communicable Diseases* / transmission
  • Cross Infection / epidemiology*
  • Cross Infection / mortality
  • Developing Countries*
  • Diarrhea* / epidemiology
  • Diarrhea* / microbiology
  • Diarrhea* / mortality
  • Drug Resistance, Microbial*
  • Global Health*
  • Humans
  • Population Surveillance*
  • Prevalence
  • Tuberculosis, Multidrug-Resistant / epidemiology*